Spero Therapeutics (SPRO) closed at $1.13 on October 22, 2026, down 3.4% from the previous close, on volume of 197,111 shares (30-day average 701,878).
Data as of October 22, 2026.
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:05 PM ET)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
Market Chameleon (Thu, 18-Jun 6:35 AM ET)
Market Chameleon (Tue, 21-Oct 7:08 AM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of October 22, 2026, SPRO stock price declined to $1.13 with 197,111 million shares trading.
SPRO has a beta of 1.33, meaning it tends to be more sensitive to market movements. SPRO has a correlation of 0.08 to the broad based SPY ETF.
SPRO has a market cap of $65.81 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC, QQQS, PRFZ.
SPRO has underperformed the market in the last year with a price return of -52.3% while the SPY ETF gained +14.9%. SPRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.1% and -3.4%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
SPRO support price is $1.12 and resistance is $1.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.
